The Global Neurodegeneration Proteomics Consortium: biomarker and drug target discovery for common neurodegenerative diseases and aging
Farhad Imam(BioVentures (United States)), Chengran Yang(Washington University in St. Louis), Timothy J. Hohman(Vanderbilt University Medical Center), Alexa Pichet Binette(Lund University), Agustı́n Ruiz(Biomedical Research Networking Center on Neurodegenerative Diseases), Laura Winchester(University of Oxford), Amelia Farinas(Neurosciences Institute), Adam L. Boxer(University of California, San Francisco), Oliver Robinson(Natural Environment Research Council), Allan I. Levey(Emory Healthcare), Inga Liepelt-Scarfone(German Center for Neurodegenerative Diseases), Andrew J. Saykin(Alzheimer’s Disease Neuroimaging Initiative), Tony Wyss‐Coray(Neurosciences Institute), Pieter Jelle Visser(Karolinska Institutet), Mika Kivimäki(University of Helsinki), Betty M. Tijms(Amsterdam Neuroscience), Chad Slawson(University of Kansas Medical Center), Varsha Krish(Gates (United States)), Roxanna Korologou‐Linden(Imperial College London), Carlos Cruchaga(Washington University in St. Louis), Rowan Saloner(University Memory and Aging Center), Erik C. B. Johnson(Emory University), Jeffrey L. Dage(Indiana University School of Medicine), Jeffrey D. Rothstein(Allen Institute for Brain Science), Niklas Mattsson(Malmö University), Eric M. Reiman(Alzheimer's Association), Muhammad Ali(Washington University in St. Louis), Oskar Hansson(Eli Lilly (United States)), Hamilton Oh(Neurosciences Institute), Martin Bringmann(Max Planck Institute of Molecular Plant Physiology), Federica Anastasi(Pasqual Maragall Foundation), Jeffrey M. Burns(Alzheimer’s Disease Neuroimaging Initiative), Keenan A. Walker(National Institutes of Health), Caitlin A. Finney(Westmead Institute for Medical Research), Artur Shvetcov(The University of Sydney), Gamal Abdel-Azim(Johnson & Johnson (United States)), Natàlia Vilor‐Tejedor(Radboud University Nijmegen), Maarten Timmers, Jacob W. Vogel(Malmö University), Marc Suárez‐Calvet(Pasqual Maragall Foundation), Mark Frasier(Michael J. Fox Foundation), Kwangsik Nho(Regenstrief Institute), Lina Lu(Lund University), Lefkos Middleton(MRC Unit for Lifelong Health and Ageing), Bart Smets, David A. Bennett, Ronald Petersen(Mayo Clinic), Lijun An(Lund University), Luigi Ferrucci(National Institute on Aging), Fernando G. Vieira(Unknown)
Cited by 85
Related Papers
Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
|Alzheimer s & Dementia|2011|7.1k
Mild cognitive impairment – beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment
|Journal of Internal Medicine|2004|5k
A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease
|Alzheimer s & Dementia|2014|3.1k
Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer’s disease risk
|Nature Genetics|2019|2.5k
Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria
|Movement Disorders|2017|2.3k